Guy Jérusalem

Research interests

Publications

• Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

  Journal of Clinical Oncology · 2024 · https://doi.org/10.1200/jco.24.00920

• Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

  Nature Medicine · 2024 · https://doi.org/10.1038/s41591-024-03261-7

• Cancer immunotherapy: it’s time to better predict patients’ response

  British Journal of Cancer · 2021 · https://doi.org/10.1038/s41416-021-01413-x

• Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.05.353

• Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.01204

• Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy

  Cancers · 2020 · https://doi.org/10.3390/cancers12030731

• Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(18)30812-x

• Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1911149

• Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30420-6

• Cardio-Oncology Services: rationale, organization, and implementation

  European Heart Journal · 2018 · https://doi.org/10.1093/eurheartj/ehy453

• Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30380-2

• Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2018.78.9909

• Codon-specific translation reprogramming promotes resistance to targeted therapy

  Nature · 2018 · https://doi.org/10.1038/s41586-018-0243-7

• Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

  Breast Cancer Research and Treatment · 2017 · https://doi.org/10.1007/s10549-017-4537-5

• Triple-negative breast cancer: treatment challenges and solutions

  Breast Cancer Targets and Therapy · 2016 · https://doi.org/10.2147/bctt.s69488

• Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

  Journal of the American Society of Echocardiography · 2014 · https://doi.org/10.1016/j.echo.2014.07.012

• Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70138-x

• Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

  European Heart Journal - Cardiovascular Imaging · 2014 · https://doi.org/10.1093/ehjci/jeu192

• Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial

  JNCI Journal of the National Cancer Institute · 2013 · https://doi.org/10.1093/jnci/djt337

• Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2010.28.8415

• Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease

  Annals of Oncology · 2002 · https://doi.org/10.1093/annonc/mdg011

• Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis.

  PubMed · 2002

• Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.

  PubMed · 2001

• Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL)

  Annals of Oncology · 2001 · https://doi.org/10.1023/a:1011169332265

• Whole-Body Positron Emission Tomography Using18F-Fluorodeoxyglucose for Posttreatment Evaluation in Hodgkin’s Disease and Non-Hodgkin’s Lymphoma Has Higher Diagnostic and Prognostic Value Than Classical Computed Tomography Scan Imaging

  Blood · 1999 · https://doi.org/10.1182/blood.v94.2.429

Current projects

No projects listed.